Ignite Creation Date:
2024-05-05 @ 11:08 AM
Last Modification Date:
2024-10-26 @ 9:04 AM
Study NCT ID:
NCT00003832
Status:
COMPLETED
Last Update Posted:
2013-01-25
First Post:
1999-11-01
Brief Title:
Broxuridine Plus Surgery in Treating Patients With Stage I or Stage II Prostate Cancer
Sponsor:
National Cancer Institute NCI
Organization:
National Cancer Institute NCI
Study Overview
Official Title:
Cell Kinetic Study of Bromodeoxyuridine BrdU in Prostate Cancer
Status:
COMPLETED
Status Verified Date:
2013-01
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
Phase II trial to study the effectiveness of broxuridine in treating patients who are undergoing surgery for stage I or stage II prostate cancer Broxuridine may help doctors determine the rate of growth of prostate tumors and help them plan effective treatment
Detailed Description:
OBJECTIVES
I Measure the potential doubling times of multifocal adenocarcinomas of the prostate using broxuridine
II Determine whether the doubling times of multifocal carcinomas occurring within a single prostate are consistent with a model in which low-volume carcinomas have slow doubling times and high-volume carcinomas have fast doubling times
OUTLINE
Patients receive broxuridine IV over 30 minutes on day -1 Approximately 12-96 hours later patients undergo surgery to remove the prostate Tumor tissue is examined by immunostaining for the presence of broxuridine to determine doubling times of the tumor
I Measure the potential doubling times of multifocal adenocarcinomas of the prostate using broxuridine
II Determine whether the doubling times of multifocal carcinomas occurring within a single prostate are consistent with a model in which low-volume carcinomas have slow doubling times and high-volume carcinomas have fast doubling times
OUTLINE
Patients receive broxuridine IV over 30 minutes on day -1 Approximately 12-96 hours later patients undergo surgery to remove the prostate Tumor tissue is examined by immunostaining for the presence of broxuridine to determine doubling times of the tumor
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None
Secondary IDs
| Secondary ID | Type | Domain | Link |
|---|---|---|---|
| CDR0000066989 | REGISTRY | PDQ Physician Data Query | None |
| 98-374 | None | None | None |